SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA’s approval for Methylprednisolone Tablets

25 Feb 2019 Evaluate

Lupin has received approval for its Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Pharmacia and Upjohn Company's Medrol tablets, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg.

Methylprednisolone Tablets had annual sales of approximately $114.3 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2503.20 0.30 (0.01%)
10-Jul-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1942.15
Dr. Reddys Labs. 1250.00
Cipla 1447.00
Zydus Lifesciences 1154.40
Lupin 2503.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: